Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib

Hospital Universitario Virgen Macarena, Hispalis, Andalusia, Spain
Annals of the Rheumatic Diseases (Impact Factor: 9.27). 11/2004; 63(11):1419-26. DOI: 10.1136/ard.2003.015974
Source: PubMed

ABSTRACT To compare the efficacy and safety of lumiracoxib with placebo and celecoxib for osteoarthritis OA in a 13 week, multicentre, randomised, double blind study.
After a 37 day washout period for nonsteroidal antiinflammatory drugs, 1702 patients with knee OA were randomised to lumiracoxib 200 or 400 mg once daily od, celecoxib 200 mg od, or placebo 2221. A visual analogue scale VAS pain intensity > or =40 mm was required. Primary efficacy variables were OA pain intensity VAS mm in the target knee, patients global assessment of disease activity VAS mm, and WOMAC pain subscale and total scores at 13 weeks. OA pain intensity, patients and physicians global assessment of disease activity, and WOMAC total and all subscale scores were analysed by visit as secondary variables.
Lumiracoxib showed significant improvements in all primary and secondary variables compared with placebo. Lumiracoxib 200 mg od and celecoxib 200 mg od achieved similar improvements in OA pain intensity and functional status. Lumiracoxib 400 mg od demonstrated better efficacy for OA pain intensity and patients global assessment of disease activity at weeks 2, 4, and 8 and similar efficacy at week 13 compared with celecoxib 200 mg od. The incidence of adverse events AEs, serious AEs, and discontinuations due to AEs was similar in each group.
Lumiracoxib demonstrated significant improvement in OA pain intensity, patients global assessment of disease activity, and the WOMAC pain subscale and total scores compared with placebo. Lumiracoxib was well tolerated in this study, with overall tolerability similar to that of placebo and celecoxib.

Download full-text


Available from: Francis Berenbaum, Apr 19, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-steroidal anti-inflammatory drugs (NSAIDs), which act via inhibition of the cyclooxygenase (COX) isozymes, were discovered more than 100 years ago. They remain a key component of the pharmacological management of acute and chronic pain. The COX-1 and COX-2 isozymes have different biological functions; analgesic activity is primarily (although not exclusively) associated with inhibition of COX-2, while different side effects result from the inhibition of COX-1 and COX-2. All available NSAIDs, including acetaminophen and aspirin, are associated with potential side effects, particularly gastrointestinal and cardiovascular effects, related to their relative selectivity for COX-1 and COX-2. Since all NSAIDs exert their therapeutic activity through inhibition of the COX isozymes, strategies are needed to reduce the risks associated with NSAIDs while achieving sufficient pain relief. A better understanding of the inhibitory activity and COX-1/COX-2 selectivity of an NSAID at therapeutic doses, based on pharmacokinetic and pharmacodynamic properties (eg, inhibitory dose, absorption, plasma versus tissue distribution, and elimination), and the impact on drug tolerability and safety can guide the selection of appropriate NSAIDs for pain management. For example, many NSAIDs with moderate to high selectivity for COX-2 versus COX-1 can be administered at doses that maximize efficacy (~80% inhibition of COX-2) while minimizing COX-1 inhibition and associated side effects, such as gastrointestinal toxicity. Acidic NSAIDs with favorable tissue distribution and short plasma half-lives can additionally be dosed to provide near-constant analgesia while minimizing plasma concentrations to permit recovery of COX-mediated prostaglandin production in the vascular wall and other organs. Each patient's clinical background, including gastrointestinal and cardiovascular risk factors, should be taken into account when selecting appropriate NSAIDs. New methods are emerging to assist clinicians in the selection of appropriate NSAIDs and their doses/schedules, such as biomarkers that may predict the response to NSAID treatment in individual patients.
    Journal of Pain Research 02/2015; 8:105-18. DOI:10.2147/JPR.S75160
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present work was conducted to examine whether celecoxib, a selective COX-2 inhibitor, 200 mg administered 1 h preoperatively to patients undergoing arthroscopic hip surgery reduces postoperative pain. Fifty-three patients undergoing arthroscopic hip surgery under spinal anesthesia were randomized to receive either 200 mg of celecoxib (Group I) or 200 mg of placebo (Group II) 1 h preoperatively. Narcotic use was monitored for 24 h, and time in recovery room was determined. Visual analog scale (VAS) scores and Short-Form 12 (SF-12), including a physical composite score (PCS) and a mental composite score (MCS), documented pain in recovery, 12 h postoperatively, and 24 h postoperatively. Moreover, time in recovery room was also investigated. We enrolled 27 patients in Group I and 26 patients in Group II. Groups were comparable for patient characteristics. No significant difference was detected in terms of VAS scores and SF-12 in recovery room. Statistically, patients in Group I showed significantly lower pain VAS scores at 12 and 24 h postoperatively. Patients taking celecoxib had significantly higher PCS at 12 and 24 h postoperatively. No difference occurred between groups for the MCS. Patients taking celecoxib also showed a significant reduction in postoperative narcotic consumption. The obtained results from the current study indicate that patients who took celecoxib 200 mg 1 h before arthroscopic hip surgery had a less painful and more rapid recovery. Celecoxib 200 mg as a single preoperative dose could be considered as part of a perioperative analgesic plan in arthroscopic hip surgery.
    European Journal of Orthopaedic Surgery & Traumatology 11/2013; 24(6). DOI:10.1007/s00590-013-1359-y · 0.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund und Fragestellung: Articulatio genus Gl D5 (AG5), ein homöopathisiertes Organpräparat wird seit Jahrzehnten zur Behandlung der Gonarthrose eingesetzt. Erstmals sollte die Wirksamkeit und Sicherheit des Präparates in einer kontrollierten Studie überprüft werden. Methode: 91 Patienten mit primärer symptomatischer Gonarthrose Kellgren & Lawrence Grad 2-3 wurden in die randomisierte, placebokontrollierte Doppelblindstudie eingeschlossen. 46 Patienten erhielten über einen Zeitraum von vier Wochen drei mal pro Woche subcutan 1 ml AG5 und 45 Patienten erhielten 1 ml Placebo (physiologische Kochsalzlösung) an das am stärksten betroffene Knie. Hauptzielkriterium war der Schmerzscore des Western Ontario and Mc Masters Questionnaire (WOMAC) nach vier Wochen Therapie und nach zwei Monaten ohne Therapie. Ergebnisse: 89 Patienten (AG5, n=44, Placebo, n=45) beendeten die Studie regulär. Sowohl unter AG5 als auch unter Placebo kam es zu einer signifikanten Verbesserung des WOMAC-Schmerzscores. Der Effekt hielt zwei Monate nach Beendigung der Therapie an (AG5: -1,9 cm, p<0,001; Placebo: -1,1 cm, p=0,003). WOMAC-Score Steifigkeit (AG5: p=0,007, Placebo: p=0,03) und WOMAC-Score Funktion (AG5: P<0,001, Placebo: p=0,017) waren ebenfalls anhaltend gebessert. Zwischen den Gruppen fand sich allerdings kein signifikanter Unterschied. Die Zahl der Patienten mit Analgetikabedarf konnte deutlich reduziert werden. Sie sank in der Placebogruppe von 53 % bei Baseline auf 29 % an Tag 84 und in der Verumgruppe von 63 % auf 15 % (p=0,115). Ernsthafte Nebenwirkungen durch das Präparat oder eine Infektion traten nicht auf. Schlussfolgerung: Eine spezifische Wirkung des Prüfpräparates konnte nicht nachgewiesen werden. Die deutlichen und anhaltenden Therapieeffekte lassen starke unspezifische Effekte durch die subcutane Injektion vermuten. Background: Articulatio genus Gl D5 (AG5) is a homoeopathic organ preparation from periarticular structures of the ox and is used for the treatment of osteoarthritis of the knee within the anthroposophic medicine. For the first time efficacy and safety of this drug were investigated in a controlled study. Methods: 91 patients with primary symptomatic osteoarthritis of the knee Kellgren & Lawrence grade 2-3 were included in this randomised placebo controlled double blind study. 46 and 45 patients respectively received three times a week subcutaneously 1 ml AG5 or 1 ml placebo (saline) in the most affected knee. Main outcome criteria was the WOMAC pain score after four weeks of therapy. Follow up was after two months without therapy. Results: 89 patients finished the study regularly (AG5 n=44, placebo n=45). In both groups the WOMAC pain scores were significantly improved. Even after two months without therapy pain, joint stiffness and function were significantly better than before treatment in both groups (mean reduction: pain AG5: -19 mm, p<0,001, placebo: -11 mm, p=0,003; stiffness AG5: p=0,007, placebo: p=0,03; function AG5: p<0,001, placebo p=0,017). However, there was no significant difference between the two groups. Also the number of patients that needed analgetics was significantly reduced: placebo baseline = 53 %, end of study = 29 %; verum 65 %, end of study = 15 % (p=0,115). There occurred no serious side effects related to the medication. Conclusion A specific effect of AG5 could not be shown in this study. The significant and long lasting effects lead to the conclusion that unspecific factors, most likely of the subcutaneous injection as such were relevant for the clinical improvement.